JP2018522867A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522867A5 JP2018522867A5 JP2017567218A JP2017567218A JP2018522867A5 JP 2018522867 A5 JP2018522867 A5 JP 2018522867A5 JP 2017567218 A JP2017567218 A JP 2017567218A JP 2017567218 A JP2017567218 A JP 2017567218A JP 2018522867 A5 JP2018522867 A5 JP 2018522867A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- hydrate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- 239000013078 crystal Substances 0.000 claims 24
- 239000000651 prodrug Substances 0.000 claims 24
- 229940002612 prodrug Drugs 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 24
- 239000012453 solvate Substances 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000004452 carbocyclyl group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 238000003419 tautomerization reaction Methods 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185366P | 2015-06-26 | 2015-06-26 | |
| US62/185,366 | 2015-06-26 | ||
| PCT/US2016/039302 WO2016210291A1 (en) | 2015-06-26 | 2016-06-24 | Fused bicyclic pyrimidine derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522867A JP2018522867A (ja) | 2018-08-16 |
| JP2018522867A5 true JP2018522867A5 (OSRAM) | 2019-07-25 |
Family
ID=57585794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567218A Pending JP2018522867A (ja) | 2015-06-26 | 2016-06-24 | 縮合二環式ピリミジン誘導体およびこれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10342798B2 (OSRAM) |
| EP (1) | EP3313529A4 (OSRAM) |
| JP (1) | JP2018522867A (OSRAM) |
| AU (1) | AU2016283100A1 (OSRAM) |
| CA (1) | CA2988461A1 (OSRAM) |
| HK (1) | HK1254469A1 (OSRAM) |
| WO (1) | WO2016210291A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CA2978518C (en) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
| EP3313530B1 (en) | 2015-06-26 | 2022-10-05 | Dana Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
| CN107698603B (zh) * | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
| CN109384782A (zh) * | 2017-08-04 | 2019-02-26 | 厦门大学 | 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 |
| CN107557370B (zh) * | 2017-09-25 | 2020-03-17 | 华南农业大学 | 水稻rel1基因在提高植物抗干旱胁迫中的应用 |
| EP3728230A1 (en) * | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| ES2971712T3 (es) | 2017-12-22 | 2024-06-06 | Hibercell Inc | Derivados de cromenopiridina como inhibidores de la fosfatidilinositol fosfato cinasa |
| WO2020005807A1 (en) | 2018-06-25 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN109879887B (zh) * | 2019-04-16 | 2021-07-20 | 辽宁大学 | 含吲哚结构的噻吩并[3,2-d]嘧啶类衍生物及其应用 |
| CN114133394B (zh) * | 2020-08-12 | 2023-12-08 | 赛诺哈勃药业（成都）有限公司 | 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途 |
| JP2023552827A (ja) * | 2020-12-09 | 2023-12-19 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| US20240277852A1 (en) * | 2021-05-20 | 2024-08-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors and degraders of pip4k protein |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| WO2023227125A1 (zh) * | 2022-05-26 | 2023-11-30 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| WO2023246371A1 (zh) * | 2022-06-24 | 2023-12-28 | 中国科学院基础医学与肿瘤研究所(筹) | 具有嘧啶并噻吩结构的小分子化合物及其应用 |
| CN119874680A (zh) * | 2025-03-27 | 2025-04-25 | 浙大城市学院 | 含2-氯丙烯酰胺的2-氨基嘧啶类化合物、其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2472619A1 (en) * | 2002-01-10 | 2003-07-24 | Bayer Corporation | Fused pyrimidine derivates as rho-kinase inhibitors |
| CA2784807C (en) * | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2013074986A1 (en) * | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| WO2013154778A1 (en) | 2012-04-11 | 2013-10-17 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
| US10112927B2 (en) * | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN103242341B (zh) * | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用 |
| CN104177363B (zh) | 2013-05-24 | 2018-06-05 | 江苏先声药业有限公司 | 双环杂环胺类Hedgehog信号通路抑制剂 |
| JP6491202B2 (ja) * | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤 |
| CA2927917C (en) | 2013-10-18 | 2022-08-09 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
-
2016
- 2016-06-24 AU AU2016283100A patent/AU2016283100A1/en not_active Abandoned
- 2016-06-24 WO PCT/US2016/039302 patent/WO2016210291A1/en not_active Ceased
- 2016-06-24 CA CA2988461A patent/CA2988461A1/en not_active Abandoned
- 2016-06-24 JP JP2017567218A patent/JP2018522867A/ja active Pending
- 2016-06-24 EP EP16815397.1A patent/EP3313529A4/en not_active Withdrawn
- 2016-06-24 HK HK18113555.0A patent/HK1254469A1/zh unknown
- 2016-06-24 US US15/737,683 patent/US10342798B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522867A5 (OSRAM) | ||
| JP2018522866A5 (OSRAM) | ||
| JP2019527682A5 (OSRAM) | ||
| TWI359813B (en) | Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4' | |
| JP2018515434A5 (OSRAM) | ||
| JP2019524883A5 (OSRAM) | ||
| JP2017537940A5 (OSRAM) | ||
| WO2023280136A1 (zh) | 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用 | |
| JP2014510774A5 (OSRAM) | ||
| CN102971312B (zh) | 吡咯取代的2-二氢吲哚酮衍生物、其制备方法及用途 | |
| JP2013500304A (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| JP2017502006A5 (OSRAM) | ||
| JP2017524733A5 (OSRAM) | ||
| JP2014508804A5 (OSRAM) | ||
| JP2018531987A5 (OSRAM) | ||
| EP3154982A1 (en) | Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction | |
| JP2016525104A5 (OSRAM) | ||
| JP2020516616A5 (OSRAM) | ||
| CN102241674A (zh) | 1,1-二甲基-β-咔啉-3-甲酰基氨基酸苄酯的合成和抗肿瘤活性评价 | |
| JP2019521964A5 (OSRAM) | ||
| US11883423B2 (en) | Nucleobase analogue derivatives and their applications | |
| CN112321568B (zh) | 4-甲基吡咯取代的吲哚酮衍生物、其制备方法及其医药用途 | |
| JPWO2021133896A5 (OSRAM) | ||
| JP2008519815A5 (OSRAM) | ||
| AU2020226633A1 (en) | Nurr1 receptor modulators |